公开(公告)号：US20120122233A1

公开(公告)日：2012-05-17

申请号：US12671823

申请日：2008-08-01

申请人： Andreas Bergmann ,  Joachim Struck ,  Nils G. Morgenthaler ,  Jana Papassotiriou ,  Stefan Blankenberg ,  Karl Lackner ,  Hans Rupprecht ,  Christoph Bickel

发明人： Andreas Bergmann ,  Joachim Struck ,  Nils G. Morgenthaler ,  Jana Papassotiriou ,  Stefan Blankenberg ,  Karl Lackner ,  Hans Rupprecht ,  Christoph Bickel

IPC分类号： G01N33/74

CPC分类号： G01N33/74 ,  G01N33/53 ,  G01N2333/585 ,  G01N2800/323 ,  G01N2800/324 ,  G01N2800/50 ,  G01N2800/54

摘要： An in vitro method for the risk stratification of patients with stable arteriosclerosis, especially stable coronary artery disease, is disclosed wherein the concentration of procalcitonin is determined in the circulation of such patients using a highly sensitive PCT assay, and wherein within the range of PCT concentrations in the typical normal range of healthy individuals cutoff values are defined which distinguish groups of individual patients with stable arteriosclerosis in accordance with personal cardiac risk, and patients are allotted to one of said risk groups on the basis of their individual PCT concentrations.

摘要翻译： 公开了用于稳定动脉硬化，特别是稳定性冠状动脉疾病的患者的风险分层的体外方法，其中使用高度敏感的PCT测定在这些患者的循环中测定降钙素原的浓度，并且其中在PCT浓度范围内 在健康人的典型正常范围内，定义了根据个人心脏风险区分稳定动脉硬化的个体患者群体的临界值，并且根据其各自的PCT浓度将患者分配到所述风险组之一。

公开(公告)号：US08735079B2

公开(公告)日：2014-05-27

申请号：US12671823

申请日：2008-08-01

申请人： Andreas Bergmann ,  Joachim Struck ,  Nils G. Morgenthaler ,  Jana Papassotiriou ,  Stefan Blankenberg ,  Karl Lackner ,  Hans Rupprecht ,  Christoph Bickel

发明人： Andreas Bergmann ,  Joachim Struck ,  Nils G. Morgenthaler ,  Jana Papassotiriou ,  Stefan Blankenberg ,  Karl Lackner ,  Hans Rupprecht ,  Christoph Bickel

IPC分类号： G01N33/53

CPC分类号： G01N33/74 ,  G01N33/53 ,  G01N2333/585 ,  G01N2800/323 ,  G01N2800/324 ,  G01N2800/50 ,  G01N2800/54

摘要： An in vitro method for the risk stratification of patients with stable arteriosclerosis, especially stable coronary artery disease, is disclosed wherein the concentration of procalcitonin is determined in the circulation of such patients using a highly sensitive PCT assay, and wherein within the range of PCT concentrations in the typical normal range of healthy individuals cutoff values are defined which distinguish groups of individual patients with stable arteriosclerosis in accordance with personal cardiac risk, and patients are allotted to one of said risk groups on the basis of their individual PCT concentrations.

摘要翻译： 公开了用于稳定动脉硬化，特别是稳定性冠状动脉疾病的患者的风险分层的体外方法，其中使用高度敏感的PCT测定在这些患者的循环中测定降钙素原的浓度，并且其中在PCT浓度范围内 在健康人的典型正常范围内，定义了根据个人心脏风险区分稳定动脉硬化的个体患者群体的临界值，并且根据其各自的PCT浓度将患者分配到所述风险组之一。

公开(公告)号：US20060105419A1

公开(公告)日：2006-05-18

申请号：US11204764

申请日：2005-08-15

申请人： Stefan Blankenberg ,  Karl Lackner ,  Hans Rupprecht ,  Christoph Bickel

发明人： Stefan Blankenberg ,  Karl Lackner ,  Hans Rupprecht ,  Christoph Bickel

IPC分类号： C12Q1/26

CPC分类号： C12Q1/28 ,  G01N33/573 ,  G01N2800/324

摘要： The present invention relates to materials and procedures for evaluating patients suffering from cardiovascular conditions, particularly acute coronary syndromes. In particular, the presence, amount, or enzymatic activity of glutathione peroxidase-1 in a patient sample, alone or in combination with one or more other markers, provides diagnostic and/or prognostic information. While applicable to diseases and conditions in which inflammation is generally manifested, the methods and compositions described herein are particularly applicable to acute coronary syndromes, including conditions selected from the group consisting of unstable angina, non-ST-elevation non-Q wave myocardial infarction, ST-elevation non-Q wave MI, and transmural (Q-wave) MI.

摘要翻译： 本发明涉及用于评价患有心血管疾病，特别是急性冠状动脉综合征的患者的材料和程序。 特别地，患者样品中单独的或与一种或多种其它标记组合的谷胱甘肽过氧化物酶-1的存在，量或酶活性提供了诊断和/或预后信息。 在适用于通常表现出炎症的疾病和病症的情况下，本文所述的方法和组合物特别适用于急性冠状动脉综合征，包括选自不稳定型心绞痛，非ST段抬高型非Q波心肌梗死， ST-elevation非Q波MI，透壁（Q波）MI。